Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC_EX:A61K39/395

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20220251191THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING CANCER IN COMBINATION WITH ANALOGS OF INTERLEUKIN PROTEINS
US 11.08.2022
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No 17527982 Applicant Arch Oncology, Inc. Inventor James BLINN

Provided are compositions and methods for treating cancer by administering antiCD47 mAbs and anti-CD47 fusion proteins with distinct functional profiles or chimeric antigen receptor (CAR)-bearing immune effector cells in combination with analogs of interleukin proteins.

2.WO/2022/166909USE OF PPAR-DELTA INHIBITOR IN COMBINATION WITH IMMUNOTHERAPEUTIC DRUG FOR PREPARING ANTI-TUMOR DRUG
WO 11.08.2022
Int.Class A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Appl.No PCT/CN2022/075135 Applicant THE FIRST HOSPITAL OF JILIN UNIVERSITY Inventor LIU, Wentao
It relates to a pharmaceutical use of a PPARδ inhibitor in combination with an immunotherapeutic drug for preparing an anti-tumor drug, wherein the immunotherapeutic drug is an immune agonist or an immune checkpoint inhibitor, the tumor is preferably melanoma, mammary cancer, ovarian cancer, pancreatic cancer, lung cancer, liver cancer, esophageal cancer, colorectal cancer, colonic cancer, lymphoma, brain tumor, sarcoma, cervical cancer, prostate cancer, bladder cancer, osteosarcoma, head and neck cancers, renal cell carcinoma, or stomach cancer. The medicine exhibits significant anti-cancer effect, strong targeting ability which has little side effect.
3.20220251177METHODS AND COMPOSITIONS RELATING TO ANTI-NUCLEOLIN RECOMBINANT IMMUNOAGENTS
US 11.08.2022
Int.Class C07K 16/18
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
Appl.No 17483101 Applicant OHIO STATE INNOVATION FOUNDATION Inventor Dario PALMIERI

Disclosed herein are methods and compositions related to single chain antibody fragments which specifically bind nucleolin (NCL). Also disclosed are treating and diagnosing diseases using single chain antibody fragments that bind nucleolin.

4.20220251192ANTI-CD33 ANTIBODIES FOR TREATING CANCER
US 11.08.2022
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No 17621815 Applicant MEMORIAL SLOAN KETTERING CANCER CENTER Inventor Nai-Kong V. Cheung

The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to the CDS 3 protein. The antibodies of the present technology are useful in methods for detecting and treating Alzheimer's disease or a CD33-associated cancer in a subject in need thereof.

5.WO/2022/169415ANTIGEN BINDING MOLECULES AND METHODS THEREOF I
WO 11.08.2022
Int.Class C07K 16/42
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
42against immunoglobulins (anti-idiotypic antibodies)
Appl.No PCT/SG2022/050042 Applicant AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH Inventor CHIN, Chui Ping, Angela
The invention relates to antigen-binding molecules that specifically bind to IgM p-chain antigen. In one embodiment, the antigen-binding molecule is an antibody that specifically binds to canine IgM p-chain antigen. Chimeric molecules of the antibody conjugated to another heterologous moiety are also provided. In one embodiment, the heterologous moiety is monomethyl auristatin E (MMAE). A method of inhibiting cancer using the antibody or the chimeric molecule thereof is also provided. In another embodiment, the antibody-MMAE conjugate suppresses tumour development in a murine model of B cell lymphoma.
6.WO/2022/166700METHOD FOR INHIBITING TUMOUR CELL GROWTH BASED ON CCDC112
WO 11.08.2022
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CN2022/073951 Applicant SHANGHAI BIOTROY BIOTECHNIQUE CO., LTD Inventor XU, Jie
The application of CCDC112 in the inhibition of tumours promotes the killing effect of immune cells on tumour cells by means of inhibiting the function or activity of CCDC112. CCDC112 has application value in the preparation of anti-tumour drugs and accompanying diagnostic markers.
7.WO/2022/166940CLDN18.2/CD3 BISPECIFIC ANTIBODIES FOR THE THERAPY OF CLDN18.2-EXPRESSING SOLID TUMORS
WO 11.08.2022
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CN2022/075326 Applicant SHANDONG BOAN BIOTECHNOLOGY CO., LTD. Inventor ZHOU, Li
The present application provides CLDN18.2 antibodies or antigen binding fragments thereof and related CLDN18.2/CD3 bispecific antibodies, as well as corresponding nucleic acids encoding same, vectors comprising such nucleic acids, host cells transfected with such nucleic acids or vectors. The present application further relates to isolated CLDN18.2 antibodies or antigen binding fragments thereof and related CLDN18.2/CD3 bispecific antibodies, pharmaceutical compositions comprising such antibodies, antigen binding fragments, bispecific antibodies, nucleic acids, vectors, or host cells and optionally a pharmaceutically acceptable carrier, and methods of treating cancer in a subject in need thereof by administering such pharmaceutical compositions. The cancers treated in accordance with the present application include CLDN18.2-positive cancers, such as, inter alia, gastric cancer and pancreatic cancer.
8.WO/2022/170090BIOMARKER FOR ASSESSING THE RISK OF DEVELOPING ACUTE COVID-19 AND POST-ACUTE COVID-19
WO 11.08.2022
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/US2022/015303 Applicant OMEROS CORPORATION Inventor DEMOPULOS, Gregory, A.
Disclosed herein are compositions, kits and methods for determining the concentration of fluid-phase MASP-2/C1-INH complex in a biological fluid, such as a biological fluid obtained from a subject infected with SARS-CoV-2. Also disclosed are methods of using said compositions, methods and kits for detection of MASP-2/C1-INH complex to determine the status of lectin pathway activation in a mammalian subject and thereby assess the risk of a subject that is or has been infected with SARS-CoV-2 for developing COVID-19-related ARDS or other poor outcome, or determine the need for treatment or efficacy of treatment of a subject in need thereof with a complement inhibitor such as a MASP-2 inhibitory agent.
9.WO/2022/170000METHODS, ASSAYS AND COMPOSITIONS FOR MEASURING BRAIN DAMAGE OR HARM DURING SURGERY
WO 11.08.2022
Int.Class G01N 33/53
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
Appl.No PCT/US2022/015155 Applicant NANOSOMIX, INC. Inventor MITSUHASHI, Masato
The present disclosure relates to methods and assays for quantifying brain-derived exosomes in biological samples from subjects before, during, and after surgery. The disclosure also provides methods and compositions for measuring and/or prognosing brain damage during surgery. The compositions and methods of the disclosure are also useful for preventing and/or treating brain damage in subjects undergoing surgery and predicting postoperative cognitive dysfunction (POCD) and/or predicting postoperative delirium (POD).
10.WO/2022/170166HTRA1-BINDING AGENTS AND METHODS OF USE THEREOF
WO 11.08.2022
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/US2022/015439 Applicant NGM BIOPHARMACEUTICALS, INC. Inventor CHU, Chun
The present disclosure provides binding agents, such as antibodies, that specifically bind HTRA1, including human HTRA1, as well as compositions comprising the binding agents, and methods of their use. The disclosure also provides related polynucleotides and vectors encoding the binding agents and cells comprising and expressing the binding agents.